Phaseline

Targets › GYRA

GYRA: drug programs, companies and trials

5 programs from 5 companies in 7 trials: 2 Phase 3, 2 Phase 4, 2 Phase 2, 1 Phase 1; Infectious disease, Respiratory, Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on GYRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assiut UniversityLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 4Bronchiectasis With Acute ExacerbationFeb 2027
Mahidol UniversityLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 4BacteremiaDec 2027
Huashan HospitalLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, TOPOISOMERASEPhase 3Multidrug Resistant Tuberculosis; Drug-resistant TuberculosisDec 2026
Copenhagen Respiratory ResearchLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 2Community-acquired Pneumonia; Community Acquired Pneumonia (CAP)Sep 2028
National University Hospital, SingaporeCiprofloxacin
Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRA, GYRBPhase 1Metastatic Pancreatic Ductal AdenocarcinomaFeb 2027

Conditions

Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1) Bronchiectasis With Acute Exacerbation (1) Community-acquired Pneumonia (1) Community Acquired Pneumonia (CAP) (1) Metastatic Pancreatic Ductal Adenocarcinoma (1) Bacteremia (1)

Modalities

small molecule (4)

Companies

Huashan Hospital (1) Assiut University (1) Copenhagen Respiratory Research (1) National University Hospital, Singapore (1) Mahidol University (1)

Related targets

GYRB (4) TOPOISOMERASE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.